Leerink Partners analyst Daina Graybosch maintained a Buy rating on Gilead Sciences (GILD – Research Report) on June 2 and set a price target of $115.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Daina Graybosch’s rating is based on Gilead Sciences’ recent positive developments in their oncology portfolio, particularly with the drug Trodelvy. The successful results from the ASCENT-04 trial, presented at the ASCO meeting, highlighted the efficacy of Trodelvy in combination with pembrolizumab for treating frontline PD-L1+ triple-negative breast cancer. This combination is expected to become a new standard of care, potentially adding significant revenue to Gilead’s portfolio.
Furthermore, the market has not fully appreciated the potential of Trodelvy, and there is an opportunity for Gilead’s stock to rise as more data becomes available, particularly from the upcoming ASCENT-03 trial. The anticipated inclusion in NCCN guidelines and potential FDA approval further strengthen the case for a Buy rating, as these developments could drive increased adoption of Trodelvy in clinical practice.
Graybosch covers the Healthcare sector, focusing on stocks such as BioNTech SE, Gilead Sciences, and Merck & Company. According to TipRanks, Graybosch has an average return of -14.3% and a 35.15% success rate on recommended stocks.
In another report released yesterday, Jefferies also maintained a Buy rating on the stock with a $130.00 price target.